Evidence map›Paper›PMID 25602521›Full record

ArticleCell cycle (Georgetown, Tex.)2015

RB loss contributes to aggressive tumor phenotypes in MYC-driven triple negative breast cancer.

Erik S Knudsen, A Kathleen McClendon, Jorge Franco, Adam Ertel, Paolo Fortina, Agnieszka K Witkiewicz

Open access · bronzeAbstract read
In one paragraph

Article in Cell cycle (Georgetown, Tex.), 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
30citing papers in PubMed, 1 pooled it
2.4field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

30 citing papers in PubMed, 1 synthesis or guideline pooled it, 38 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Article
  4. Article
  5. Article
  6. Review
  7. Article
  8. Article
  9. Review
  10. Article
  11. Article
  12. Review
  13. Article
  14. Article
  15. Review
  16. Review
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 5 institutions in 2 countries.

Erik S Knudsena Simmons Cancer Center; UT Southwestern ; Dallas , TX USA.
A Kathleen McClendon
Jorge Franco
Adam Ertel
Paolo Fortina
Agnieszka K Witkiewicz
Philadelphia University · USHarold C. Simmons Comprehensive Cancer CenterSimmons University · USSouthwestern Medical Center · USThomas Jefferson University · US

Funding

X-Ray Crystallography and Macromolecular CharacterizationP30CA056036 · NCI · THOMAS JEFFERSON UNIVERSITY · PI Andrew Chapman · 1995 to 2026
$94.8M
Action of RB Pathway in Breast Cancer TherapyR01CA129134 · NCI · UT SOUTHWESTERN MEDICAL CENTER · PI KNUDSEN, ERIK · 2010 to 2014
$1.7M
Pathway Heterogeneity: Etiology and Treatment of TNBCR01CA188650 · NCI · UT SOUTHWESTERN MEDICAL CENTER · PI KNUDSEN, ERIK · 2014 to 2018
$1.7M
Impact of ErbB2 and RB Pathways on DCIS Progression and TreatmentR01CA163863 · NCI · UT SOUTHWESTERN MEDICAL CENTER · PI WITKIEWICZ, AGNIESZKA · 2012 to 2016
$1.6M
Impact of Cyclin D1 Isoforms in Breast CancerR01CA137494 · NCI · THOMAS JEFFERSON UNIVERSITY · PI KNUDSEN, ERIK, PESTELL, RICHARD G · 2010 to 2014
$1.5M
NCI NIH HHS CA129134NCI NIH HHS CA137494NCI NIH HHS CA163863NCI NIH HHS P30 CA056036NCI NIH HHS R01 CA129134NCI NIH HHS R01 CA163863NCI NIH HHS R01 CA188650
6 · The paper itself

Abstract

Triple negative breast cancer (TNBC) is characterized by multiple genetic events occurring in concert to drive pathogenic features of the disease. Here we interrogated the coordinate impact of p53, RB, and MYC in a genetic model of TNBC, in parallel with the analysis of clinical specimens. Primary mouse mammary epithelial cells (mMEC) with defined genetic features were used to delineate the combined action of RB and/or p53 in the genesis of TNBC. In this context, the deletion of either RB or p53 alone and in combination increased the proliferation of mMEC; however, the cells did not have the capacity to invade in matrigel. Gene expression profiling revealed that loss of each tumor suppressor has effects related to proliferation, but RB loss in particular leads to alterations in gene expression associated with the epithelial-to-mesenchymal transition. The overexpression of MYC in combination with p53 loss or combined RB/p53 loss drove rapid cell growth. While the effects of MYC overexpression had a dominant impact on gene expression, loss of RB further enhanced the deregulation of a gene expression signature associated with invasion. Specific RB loss lead to enhanced invasion in boyden chambers assays and gave rise to tumors with minimal epithelial characteristics relative to RB-proficient models. Therapeutic screening revealed that RB-deficient cells were particularly resistant to agents targeting PI3K and MEK pathway. Consistent with the aggressive behavior of the preclinical models of MYC overexpression and RB loss, human TNBC tumors that express high levels of MYC and are devoid of RB have a particularly poor outcome. Together these results underscore the potency of tumor suppressor pathways in specifying the biology of breast cancer. Further, they demonstrate that MYC overexpression in concert with RB can promote a particularly aggressive form of TNBC.

Indexed as

AnimalsCell Culture TechniquesCell MovementCell ProliferationCells, CulturedDown-RegulationEpithelial CellsEpithelial-Mesenchymal TransitionFemaleHumansMammary Glands, AnimalMiceMice, NudeMitogen-Activated Protein Kinase KinasesPhenotypePhosphatidylinositol 3-KinasesMitogen-Activated Protein Kinase KinasesPhosphatidylinositol 3-KinasesProto-Oncogene Proteins c-mycRetinoblastoma ProteinTumor Suppressor Protein p53basal-like breast cancerbiomarkerscell cycleEMTMYCp53RB tumor suppressortargeted therapyTriple negative breast cancer

Identifiers

PMID25602521
PMCPMC4353068
OpenAlexW2006096599

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.